New direction for Alzheimer's research?

Pharmawire examines the likely impact that the failure of the late-stage trial for Flurizan will have on R&D projects in the Alzheimer's arena. Experts say that the research could now head in a new direction. Article

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.